Marooned in a parallel universe in war-torn Lebanon, James Pollack finds a mysterious time-travelling medallion. Meanwhile, some fifty years in the future, his companions and former lover fight to stay alive. Earth has changed. The landscape is dangerous and genetic mutations have wiped out the male species. Will James be able to get his female companions safely home? Learn more about this book and the author: http://www.independentauthornetwork.com/andrew-man.html Thriller
In his new book, award-winning author Donovan Webster embarks on an epic journey to meet his ancestral human family, following the path set by his DNA some 60,000 years ago. Meeting the Family is part genetic science, part travelogue, and totally fascinating. Learn more about this book here: http://tinyurl.com/35rfr3x Non-fiction
Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
Released today, The Aging Myth is an explosive new book by noted scientist and anti-aging researcher Joseph Chang, Ph.D., that reveals how new genetic discoveries are challenging traditional anti-aging philosophies and helping people live younger longer. In The Aging Myth, Dr. Chang uses a conversational and accessible style to dispel common myths about aging and explains some of the latest groundbreaking research in the field.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/nuskin/50881/
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
Weight loss is perhaps the most common New Year’s resolution made and likely the most difficult to keep. Amway North America offers the NUTRILITE® Weight Management Program, which includes a genetic test that helps individuals find their genotype-matched diet, and offers weight management plans matched to that gene test’s results.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53285-amway-nutrilite-weight-management-program-new-year-resolutions-julie-upton
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
In collaboration with the National Institutes of Health (NIH), Banner Alzheimer’s Institute (BAI), University of Antioquia in Colombia and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announce the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. This groundbreaking study—the first to investigate whether an anti-amyloid treatment can stave off the disease—will span two countries and help launch a new era of prevention research in the urgent fight against Alzheimer’s.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56128-banner-alzheimer-s-institute-genentech-nih-prevention-trial-genetics
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development.
Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
Amway North America today launched BODYKEY by NUTRILITE™, a weight management program rooted in genetics that reveals exactly how a person should eat to most effectively manage their weight.
BODYKEY by NUTRILITE weight loss plans are based on an individual’s unique genetic makeup. The new program combines eating well, fitness, nutrition and a take-at-home genetic test to determine if a person’s body responds better to cutting carbs, reducing fat or a balanced diet.
To view Multimedia News Release, go to http://www.multivu.com/players/English/60257-amway-bodykey/
Persistent deterioration of short-term memory, progressive confusion and disorientation and frequent agitation are characteristic of Alzheimer’s disease. We have been told that it is largely genetic but that there are some things that can be done to reduce the severity or how early the onset is. We can’t change our genetic makeup but we can change our behavior to help mitigate the effects of this type of dementia. These are all things we can accomplish with a little determination and planning. http://youtu.be/9eMrmVMuAa0
